Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound anisodine is a pharmaceutical drug that is a combination preparation containing anisodine hydrobromide and procaine hydrochloride. Anisodine hydrobromide, a tropane alkaloid derived from Anisodus tanguticus, acts as a muscarinic acetylcholine receptor antagonist and an alpha-1 adrenergic receptor antagonist. It also possesses vasodilatory properties and improves microcirculation. Procaine hydrochloride contributes antioxidant and neuroprotective activities. The drug is primarily used in China for various ophthalmic conditions, including ischemic optic neuropathy, retinopathy, choroidopathy, and glaucoma, by regulating the vegetative nervous system, improving microcirculation, relieving vasospasm, increasing blood flow, and protecting optic nerves.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound anisodine.